Lacosamide for Focal Seizures
Lacosamide is indicated as adjunctive therapy or monotherapy for focal (partial-onset) seizures in adults and children aged ≥4 years, administered orally or intravenously at target doses of 200-400 mg/day in adults (or 8-12 mg/kg/day in children <30 kg), with both routes demonstrating equivalent tolerability profiles. 1, 2
Indications
Lacosamide is FDA-approved specifically for focal-onset seizures (previously termed partial-onset seizures) in patients aged 4 years and older. The evidence from guideline-level sources confirms its use in this population 1. While older guidelines from 2004 do not specifically mention lacosamide (as it was approved later), the 2014 emergency medicine guidelines explicitly address its use 1.
Key indication criteria:
- Focal seizures with or without secondary generalization
- Age ≥4 years (pediatric efficacy extrapolated from adult data with appropriate dose adjustments) 3
- Can be used as adjunctive therapy or monotherapy 3
Dosing Regimen
Adults and Adolescents (≥16 years)
Initial and titration:
- Start at 100 mg/day (50 mg twice daily)
- Increase weekly by 100 mg/day increments
- Target maintenance: 200-400 mg/day (divided twice daily)
- Maximum approved dose: 400 mg/day 4, 5
Flexible dosing approach: In real-world practice, intermediate doses can be used during titration for patients sensitive to new antiepileptic drugs, with dose escalation over 12 weeks showing improved tolerability 4.
Pediatric Patients (4 to <17 years)
Weight-based dosing: 2
- <30 kg: 8-12 mg/kg/day (oral solution)
- ≥30 to <50 kg: 6-8 mg/kg/day (oral solution)
- ≥50 kg: 300-400 mg/day (tablets)
Titration: 6-week titration period to target dose, followed by maintenance 2
Children <4 Years
Recent evidence shows lacosamide did not demonstrate superior efficacy versus placebo in children aged 1 month to <4 years, though it was generally well tolerated 6. The failure may relate to high variability in video-EEG interpretation rather than true lack of efficacy. Use in this age group remains off-label and should be approached cautiously.
Administration Routes
Both oral and intravenous routes are equally effective and well-tolerated 1. The critical finding from the 2008 Biton study showed that IV lacosamide has a tolerability profile consistent with oral lacosamide, with all adverse effects being mild or moderate 1.
Route selection:
- Oral: Tablets (≥50 kg) or oral solution (<50 kg)
- IV: When oral route unavailable; patients can be switched between routes at same dosage 3
- Subcutaneous: Emerging evidence suggests feasibility for palliative care situations, though this remains off-label 7
Important caveat: The guideline evidence notes that patients in these studies were not loaded with lacosamide 1, distinguishing it from traditional loading protocols used with phenytoin or other agents in acute seizure management.
Safety Considerations
Common Adverse Effects
Most frequent treatment-emergent adverse events (dose-related): 5
- Dizziness (30.6% vs 8.2% placebo) - most common
- Nausea (11.4% vs 4.4% placebo)
- Diplopia (10.5% vs 1.9% placebo)
- Headache, somnolence, back pain 1
Critical pattern: These adverse effects are predominantly seen during titration phase and decrease during maintenance, supporting slower titration strategies 5.
Serious Adverse Effects
Cardiac concerns: 8
- Rhythm and conduction disturbances
- Mandatory ECG monitoring in patients with cardiac disease
- Avoid in patients with known conduction abnormalities
Dermatologic reactions: 8
- DRESS syndrome (Drug Rash with Eosinophilia and Systemic Symptoms)
- Use caution in patients with allergy history
- Cross-reactivity concerns with other antiepileptic drugs
Psychiatric effects: 8
- Depression and psychosis risk
- Avoid or intensively monitor in patients with psychiatric history
- Consider alternative agents if psychiatric disorders present
Metabolic monitoring: 8
- Periodic serum sodium monitoring (hyponatremia risk with eslicarbazepine, though less documented with lacosamide)
- No significant weight changes or clinical chemistry abnormalities in pooled trials 5
Discontinuation Rates
Dose-dependent discontinuations due to adverse events: 5
- 200 mg/day: 8.1%
- 400 mg/day: 17.2%
- 600 mg/day: 28.6%
- Placebo: 4.9%
The 400 mg/day dose represents the optimal balance between efficacy and tolerability, as 600 mg/day shows substantially higher discontinuation without proportional benefit.
Drug Interactions
Concomitant antiepileptic drugs affect lacosamide levels: 9
- Non-hepatic enzyme-inducing AEDs increase serum concentration and concentration-to-dose ratio
- Body weight and weight-adjusted dose are independent predictors of serum concentration
- Age influences exposure, requiring dynamic dose optimization in children
Common co-medications and discontinuation rates: 5
- Carbamazepine: 15.3% discontinuation (vs 3.9% placebo)
- Lamotrigine: 19.2% discontinuation (vs 4.3% placebo)
- Levetiracetam: 10.1% discontinuation (vs 3.9% placebo)
Pediatric Safety Profile
In children aged 4-17 years, lacosamide was generally well tolerated with treatment-emergent adverse events in 67.8% (vs 58.1% placebo), most commonly somnolence (14.0%) and dizziness (10.5%) 2. The safety profile is consistent with adults, supporting its use across age groups ≥4 years 3.
Clinical Efficacy
Adults: 31.7% reduction in focal seizure frequency versus placebo (p=0.0003), with 50% responder rates of 52.9% (vs 33.3% placebo) in pediatric patients 2. Long-term efficacy sustained up to 8 years in adults 3.
Monotherapy: Demonstrated non-inferiority to carbamazepine controlled-release for seizure freedom 3.
Common Pitfalls to Avoid
- Too-rapid titration: Increases dizziness and nausea; use weekly 100 mg increments minimum
- Ignoring cardiac history: Always obtain ECG in patients with cardiac disease before initiating
- Overlooking psychiatric history: Screen for depression/psychosis risk before prescribing
- Using in children <4 years without understanding limitations: Recent evidence shows lack of demonstrated efficacy in this age group 6
- Assuming loading protocols apply: Unlike phenytoin, lacosamide studies did not use loading doses 1